Sartorius Stedim: Recurring EBITDA virtually flat in 2024
(CercleFinance.com) - Sartorius Stedim Biotech reported a 43.
6% drop in net income to E175.1m for 2024, or E1.81 per share, but almost flat recurring EBITDA (-0.8%) to E779m, representing a margin that is down 0.3 point to 28%.
The supplier of products and services to the pharmaceutical industry's sales were steady (+0.2%) at E2.78bn. At constant exchange rates, sales rose by 0.6%, while order intake climbed by 12.9%.
It is encouraging to note that the trend is increasingly positive, and that business accelerated considerably in H2 and particularly in Q4, management said.
For 2025, Sartorius Stedim Biotech expects profitable growth above the market, with a moderate increase in sales, and anticipates that its recurring EBITDA will grow significantly faster than sales.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
6% drop in net income to E175.1m for 2024, or E1.81 per share, but almost flat recurring EBITDA (-0.8%) to E779m, representing a margin that is down 0.3 point to 28%.
The supplier of products and services to the pharmaceutical industry's sales were steady (+0.2%) at E2.78bn. At constant exchange rates, sales rose by 0.6%, while order intake climbed by 12.9%.
It is encouraging to note that the trend is increasingly positive, and that business accelerated considerably in H2 and particularly in Q4, management said.
For 2025, Sartorius Stedim Biotech expects profitable growth above the market, with a moderate increase in sales, and anticipates that its recurring EBITDA will grow significantly faster than sales.
Copyright (c) 2025 CercleFinance.com. All rights reserved.